B + L Announces Publication of Phase 4 Data on the Early Effects of MIEBO® on Patient-Reported Outcomes in Dry Eye Disease in Ophthalmology and Therapy Journal
Thursday, March 20 2025 | 14 h 20 min | News
Bausch + Lomb Corporation announced Ophthalmology and Therapy has published results from a phase 4 study which assessed early patient-reported...
Read More Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences
Friday, January 24 2025 | 15 h 44 min | News
Bausch + Lomb Corporation announced an affiliate has acquired Whitecap Biosciences, LLC, which is currently developing two innovative therapies for...
Read More Bausch + Lomb and Glaucoma Research Foundation Launch Second Annual Faces of Glaucoma Campaign and Fundraising Challenge
Tuesday, January 7 2025 | 10 h 29 min | News
Bausch + Lomb Corporation and Glaucoma Research Foundation (GRF), a national nonprofit organization dedicated to curing glaucoma, are launching the...
Read More Bausch + Lomb Responds to Rumors of a Potential Sale
Friday, December 13 2024 | 09 h 17 min | News
Bausch + Lomb Corporation issued the following statement in response to a request from the Canadian Investment Regulatory Organization...
Read More Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment Capabilities
Thursday, December 12 2024 | 13 h 03 min | News
Bausch + Lomb Corporation announced that an affiliate has acquired Elios Vision, Inc, developer of the ELIOS™ procedure, the first clinically...
Read More
